Clinical Trial Update: FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC [Phase 1, Phase 2]

View source ↗

Summary

First-in-human Phase 1/2 trial of the NaPi2b-targeted antibody-drug conjugate TUB-040 assessing safety, PK, and preliminary efficacy in patients with platinum-r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Ovarian Cancer

Drugs mentioned

• TUB-040 (NaPi2b-targeted antibody-drug conjugate)

Snippet

Sponsor: Tubulis GmbH | Conditions: Ovarian Cancer, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING